Status:
COMPLETED
A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.
Lead Sponsor:
Boehringer Ingelheim
Conditions:
HIV Infections
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to mo...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- HIV-1 infected patients who are treatment experienced and infected with HIV-1 strains resistant to more than one protease inhibitor and no other therapeutic options.
- The inclusion criteria follow the same criteria which are describe in the newest SPC
- Exclusion criteria:
- The exclusion criteria follow the same criteria which are describe in the newest SPC
Exclusion
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2011
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00976950
Start Date
September 1 2009
End Date
July 1 2011
Last Update
March 20 2014
Active Locations (20)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational site 9
Arad, Romania
2
Boehringer Ingelheim Investigational site 13
Bacau, Romania
3
Boehringer Ingelheim Investigational site 17
Brasov, Romania
4
Boehringer Ingelheim Investigational site 18
Brasov, Romania